Article

In 1993, the US Food and Drug Administration (FDA) approved the first drug
specifically for treating multiple sclerosis (MS). More than two decades later, a
dozen such treatments are now available. Of these, four are considered
second-line treatments for use in escalation strategies and two new drugs are
currently undergoing accreditation procedures.
Soon, they will provide clinicians
with a range of six effective disease-modifying treatments (DMTs) to thwart the
inflammatory processes in MS patients with active disease. However, while such a
large number of DMTs for MS can help to control early inflammation, any decisions
to be made by clinicians have also been made substantially more complex. This
complexity is increased by the lack of head-to-head studies comparing these
second-line therapies and the benefit-risk profiles for each of these drugs,
which are likely to vary among patients. Ultimately, good awareness of the
benefits and, more important, the risks of each MS DMT is crucial for the
effective management of inflammation in MS.
CI - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.

Langue : ANGLAIS